BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 9723701)

  • 1. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.
    Wilson AD; Redchenko I; Williams NA; Morgan AJ
    Int Immunol; 1998 Aug; 10(8):1149-57. PubMed ID: 9723701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
    Nikiforow S; Bottomly K; Miller G; Münz C
    J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.
    Long HM; Zuo J; Leese AM; Gudgeon NH; Jia H; Taylor GS; Rickinson AB
    Blood; 2009 Jul; 114(4):807-15. PubMed ID: 19443664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
    MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
    J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
    Nikiforow S; Bottomly K; Miller G
    J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
    Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
    Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression.
    Fu Z; Cannon MJ
    J Virol; 2000 Jul; 74(14):6675-9. PubMed ID: 10864684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.
    Wilson AD; Hopkins JC; Morgan AJ
    Clin Exp Immunol; 2001 Oct; 126(1):101-10. PubMed ID: 11678905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
    Wilson AD; Morgan AJ
    J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T-cell apoptosis.
    Tanner JE; Alfieri C
    Blood; 1999 Nov; 94(10):3439-47. PubMed ID: 10552954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
    Lewinsohn DM; Bement TT; Xu J; Lynch DH; Grabstein KH; Reed SG; Alderson MR
    J Immunol; 1998 Mar; 160(5):2374-9. PubMed ID: 9498779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of Epstein-Barr virus-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis.
    Enssle KH; Fleischer B
    Clin Exp Immunol; 1990 Mar; 79(3):409-15. PubMed ID: 1690617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4
    Choi IK; Wang Z; Ke Q; Hong M; Qian Y; Zhao X; Liu Y; Kim HJ; Ritz J; Cantor H; Rajewsky K; Wucherpfennig KW; Zhang B
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E686-E695. PubMed ID: 29311309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells.
    Schattner EJ; Mascarenhas J; Bishop J; Yoo DH; Chadburn A; Crow MK; Friedman SM
    Blood; 1996 Aug; 88(4):1375-82. PubMed ID: 8695856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD80 (B7.1) and CD86 (B7.2) induce EBV-transformed B cell apoptosis through the Fas/FasL pathway.
    Park GB; Kim YS; Lee HK; Cho DH; Kim D; Hur DY
    Int J Oncol; 2013 Nov; 43(5):1531-40. PubMed ID: 24008628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
    Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
    Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells.
    Khanolkar A; Yagita H; Cannon MJ
    Virology; 2001 Aug; 287(1):79-88. PubMed ID: 11504544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.